Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Vaccinium myrtillus* leaf extract, derived from the leaves of the bilberry plant, is a botanical extract traditionally utilized in folk medicine for the management of hyperglycemia and metabolic disorders. The extract is characterized by a high concentration of polyphenolic compounds, including chlorogenic acid, quercetin derivatives, rutin, and hyperoside. Its primary therapeutic mechanism involves the inhibition of key carbohydrate-metabolizing enzymes, specifically alpha-glucosidase and alpha-amylase, which serves to delay glucose absorption and reduce postprandial blood sugar levels. Recent research has explored its potential synergistic effects when combined with prebiotic fibers like inulin. Currently, it is primarily investigated as a functional food ingredient or nutraceutical for managing type 2 diabetes and improving glycemic control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaccinium myrtillus leaf extract.